Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy

Asai, Nobuhiro; Ohkuni, Yoshihiro; Matsunuma, Ryo; Nakashima, Kei; Iwasaki, Takuya; Kaneko, Norihiro

doi:10.4103/0973-1482.98983

Cited by 11 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While some argued in favor of the efficacy of third-line chemotherapy for SCLC [Park et al 2007;Igawa et al 2007;Asai et al 2012], there is a lack of data showing its efficacy. More studies should be conducted to establish the third-line treatment of relapsed SCLC.…”

Section: Third-line Chemotherapymentioning

confidence: 99%

Relapsed small cell lung cancer: treatment options and latest developments

et al. 2014

Self Cite

View full text Add to dashboard Cite

According to recent analyses, there was a modest yet significant improvement in median survival time and 5-year survival rate of limited stage small cell lung cancer (SCLC) in North America, Europe, Japan and other countries over the last 30 years. The median survival time of limited stage SCLC is 15-20 months and 5-year survival rate is 15% or less. In terms of extensive stage SCLC, a median survival time of 9.4-12.8 months and 2-year survival of 5.2-19.5% are still disappointing. Despite being highly sensitive to first-line chemotherapy and radiotherapy treatments, most patients with SCLC experience relapse within 2 years and die from systemic metastasis. While several clinical trials of cytotoxic chemotherapies and molecular targeting agents have been investigated in the treatment of relapsed SCLC, none showed a significant clinical activity to be able to exceed topotecan as second-line chemotherapy. There are problematic issues to address for relapsed SCLC, such as standardizing the treatment for third-line chemotherapy. Topotecan alone was the first approved therapy for second-line treatment for relapsed SCLC. Amrubicin is a promising drug and a variety of trials evaluating its efficacy have been carried out. Amrubicin has shown superiority to topotecan in a Japanese population, but was not superior in a study of western patients. There are some controversial issues for relapsed SCLC, such as treatment for older patients, third-line chemotherapy and efficacy of molecular targeting therapy. This article reviews current standard treatment, recent clinical trials and other topics on relapsed SCLC.

show abstract

Section: Third-line Chemotherapymentioning

confidence: 99%

Relapsed small cell lung cancer: treatment options and latest developments

et al. 2014

Self Cite

View full text Add to dashboard Cite

show abstract

“…With regard to the treatment of amrubicin as third‐line chemotherapy, there have been two retrospective clinical studies in Japan. Although the sample sizes were small in both studies, the response rates were 14% and 44.0%, respectively. In the present study, the response rate (27.8%) and time from amrubicin monotherapy until time of death (5.2 months) were comparable to these studies.…”

Section: Discussionmentioning

confidence: 81%

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute

et al. 2019

View full text Add to dashboard Cite

Background The efficacy of amrubicin for relapsed small‐cell lung cancer (SCLC) has been reported in previous studies. Few reports, however, describe the efficacy and survival benefit of third‐line amrubicin chemotherapy in patients with extensive disease (ED)‐SCLC. Methods We retrospectively analyzed the clinical records of ED‐SCLC patients treated with amrubicin salvage chemotherapy as a third‐line chemotherapy between January 2005 and July 2016 (salvage amrubicin group). The efficacy and toxicities of amrubicin were evaluated. Overall survival (OS) in the amrubicin salvage group was compared with OS among ED‐SCLC patients treated with at least second‐line chemotherapy between May 2000 and July 2016 and without subsequent amrubicin salvage chemotherapy. Results A total of 18 patients with a median age of 70 years were analyzed in the amrubicin salvage group. The median number of treatment cycles of amrubicin was four. The response rate was 27.8% (95% confidence interval (CI), 7.1%–48.5%), and the disease control rate (DCR) was 66.7% (95% CI, 44.9%–88.4%). Median progression‐free survival was 2.9 months (95% CI, 1.0–4.9 months), and median OS after an initial chemotherapy was 18.1 months (95% CI, 10.2–26.0 months). OS in the amrubicin salvage group was significantly longer than in the no‐amrubicin group (n = 19; 12.6 months, 95% CI, 11.5–13.8 months, P = 0.005). The frequency of neutropenia greater than grade 3 was 72.2%, with febrile neutropenia developing in 38.9% of patients in the amrubicin salvage group. Conclusions Despite a high frequency of febrile neutropenia, amrubicin salvage chemotherapy may improve OS in patients with relapsed ED‐SCLC.

show abstract

“…Regarding third line chemotherapy, a previous study regarding the use of amrubicin for refractory relapsed SCLC was undertaken. The results of this study included a PFS period of 3.0 months and an OS period of 5.1 months . Additionally, another study regarding amrubicin therapy in the setting of refractory SCLC was performed.…”

Section: Discussionmentioning

confidence: 99%

“…The results of this study included a PFS period of 3.0 months and an OS period of 5.1 months. 10 Additionally, another study regarding amrubicin therapy in the setting of refractory SCLC was performed. Eighty-two patients with chemotherapy-refractory SCLC received 40 mg/m 2 of amrubicin for three consecutive days, every 21 days.…”

Section: Discussionmentioning

confidence: 99%

Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine (CAV) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer

Jung

Kim

et al. 2015

Thoracic Cancer

View full text Add to dashboard Cite

Third and fourth line chemotherapy agents are not helpful in the setting of extensive stage small cell lung cancer (SCLC). We describe the case of a 43-year-old Korean patient with T4N3M1b extensive stage SCLC who responded remarkably well to treatment and experienced a prolonged progression-free survival (PFS) period following treatment with fourth line ifosfamide and carboplatin after experiencing disease progression with three previous regimens. Additionally, third line cyclophosphamide, doxorubicin (Adriamycin), and vincristine demonstrated long-term PFS periods.

show abstract

Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy

Abstract: AMR could be one of the effective tools in the treatment of elderly patients with refractory relapsed SCLC as third-line chemotherapy, and the recommended dose is 30 mg/m 2 for three consecutive days.

Cited by 11 publications

References 22 publications

Relapsed small cell lung cancer: treatment options and latest developments

Relapsed small cell lung cancer: treatment options and latest developments

The efficacy of amrubicin third‐line chemotherapy in patients with relapsed extensive‐disease small‐cell lung cancer: A retrospective and historical study in a single institute

Promising effects of 3rd line cyclophosphamide, adriamycin and vincristine (CAV) and 4th line ifosfamide and carboplatin chemotherapy in refractory small cell lung cancer

Contact Info

Product

Resources

About